Drug Sales Trends for GEODON

Payment Methods and Pharmacy Types for GEODON (2012)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$7,242,245
INSIDE ANOTHER STORE	$55,851,274

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	4,681
INSIDE ANOTHER STORE	121,885

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$266,040,612
MEDICARE	$184,196,759

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for GEODON

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
GEODON			2022
GEODON			2021
GEODON			2020

GEODON (Ziprasidone) Market Analysis, Patent Status, and Sales Projections

Last updated: September 2, 2026

GEODON, the Pfizer-developed brand of ziprasidone, is a mature antipsychotic with minimal branded revenue and an established generic market. U.S. patent protection has expired, FDA generic competition is entrenched, and no biosimilar pathway applies. Future market value will depend on generic prescription volume, institutional use, pricing, and competition from aripiprazole, quetiapine, risperidone, olanzapine, lurasidone, cariprazine, and long-acting injectable therapies.

A reasonable base-case estimate places the global ziprasidone market at approximately $150 million to $300 million annually in 2025, with the U.S. generic segment representing roughly $75 million to $125 million. The market is likely to remain broadly stable in prescription volume but decline in nominal pricing as generic suppliers compete.

What is GEODON and what indications does it have?

GEODON is the brand name for ziprasidone hydrochloride, an atypical antipsychotic marketed primarily in oral capsules and intramuscular injection form.

Product	Strengths or presentation	FDA-approved use
Ziprasidone capsules	20 mg, 40 mg, 60 mg, 80 mg	Schizophrenia; acute manic or mixed episodes associated with bipolar I disorder
Ziprasidone injection	20 mg/mL	Acute agitation associated with schizophrenia
Brand	GEODON	Pfizer-originated product
Generic	Ziprasidone hydrochloride	Approved through abbreviated new drug applications

The oral formulation must be taken with food. The FDA label specifies a meal providing at least 500 calories because food materially increases exposure to ziprasidone.[1] This administration requirement limits convenience compared with products that can be taken without regard to meals.

Ziprasidone also carries a clinically important QT-prolongation warning. The product label identifies a greater capacity to prolong the QT/QTc interval than several other antipsychotics and contraindicates use in patients with known QT prolongation or certain significant cardiac risks.[1]

What is the FDA regulatory status of GEODON?

GEODON was approved by the FDA in 2001 for schizophrenia. The FDA later approved additional uses for acute manic or mixed episodes associated with bipolar disorder and intramuscular treatment of acute agitation in schizophrenia.[2]

The product is no longer a growth-stage branded asset. Its commercial status is:

Regulatory issue	Status
Original NDA	Approved
Active brand development	Mature product
Generic availability	Established
Prescription route	Oral and intramuscular
Biosimilar eligibility	Not applicable
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired
U.S. brand growth profile	Declining or negligible
U.S. generic substitution	High

The oral capsule and injectable products remain FDA-approved dosage forms, but approval does not imply meaningful continuing revenue for the branded product. Generic availability has shifted the economic value from the originator to manufacturers that compete on supply reliability, contracts, and distribution.

When does GEODON lose exclusivity?

GEODON lost meaningful U.S. market exclusivity after expiration of the principal ziprasidone patent estate and the launch of generic products in 2013.

Historical exclusivity timeline

Event	Approximate timing
GEODON FDA approval	2001
Core compound patent protection	Expired in the early 2010s
Generic ziprasidone approvals	2013
Full generic substitution pressure	2013 onward
Pediatric exclusivity	Expired
Current brand exclusivity	None of commercial significance

The principal U.S. compound patent associated with ziprasidone was U.S. Patent No. 5,312,925, which had an effective term extending into 2012, subject to applicable patent-term adjustments and extensions. The FDA approved generic ziprasidone products after the relevant patent and regulatory barriers were addressed.[3][4]

Current commercial analysis should treat ziprasidone as an off-patent small molecule. There is no biologic exclusivity period and no biosimilar litigation framework relevant to the product.

What patents protect GEODON?

The core GEODON patent estate is no longer a meaningful barrier to generic entry.

Patent category	Commercial status
Ziprasidone compound patent	Expired
Oral capsule claims	No effective barrier to ordinary generic entry
Intramuscular formulation claims	No known broad remaining barrier to established generic competition
Method-of-use claims	Historical protection has expired or lacks practical exclusivity value
Manufacturing patents	Potentially relevant to individual suppliers but not a market-wide barrier
Orange Book protection	No current listed patent should be treated as a material block to standard generic supply without checking the current FDA database

The relevant distinction is between market-level protection and supplier-specific intellectual property. A generic manufacturer may hold process, polymorph, crystallization, or manufacturing know-how. Those rights can protect a particular production route but generally do not prevent other suppliers from producing approved ziprasidone through a noninfringing process.

What formulations are protected by GEODON patents?

Historical protection centered on ziprasidone as an active pharmaceutical ingredient and the approved dosage forms. The commercial opportunity today is not based on exclusivity for the original capsule formulation. Generic manufacturers can sell the same strengths if they demonstrate pharmaceutical equivalence and bioequivalence under the ANDA pathway.

Potential formulation differentiation could include:

• Modified-release oral products
• Alternative administration formats
• Improved food-independence
• Long-acting injectable formulations
• Hospital-ready injection packaging
• Combination products

No such product should be assumed to have FDA approval or commercially relevant patent protection without a separate product-specific review.

What is the Orange Book status of GEODON?

The FDA Orange Book identifies approved drug products, therapeutic equivalence information, and, where applicable, patents and exclusivity associated with listed products.[3]

For GEODON, the important commercial conclusion is that the Orange Book no longer provides the originator with a meaningful barrier to ordinary generic substitution. The product’s current risk profile is driven by approved generic equivalents rather than pending Paragraph IV challenges to a live, high-value brand patent.

Orange Book analysis should distinguish between:

1. Historical patents listed for the original NDA.
2. Expired patents that no longer block approval or launch.
3. Current patents, if any, associated with specific listed products.
4. Regulatory exclusivity, which has expired for the original product.

Which companies challenged GEODON patents?

Generic manufacturers challenged or worked around the historical GEODON patent estate during the pre-generic-entry period. The most important commercial event was not a current challenge but the subsequent FDA approval and launch of generic ziprasidone products.

The generic market has included major and specialty suppliers such as:

• Teva Pharmaceuticals
• Sandoz
• Zydus
• Lupin
• Alembic
• Dr. Reddy’s Laboratories
• Torrent Pharmaceuticals
• Other ANDA holders and contract manufacturers

The exact active supplier set changes over time because manufacturers enter, exit, discontinue specific strengths, or maintain approval without continuous commercial supply.

What Paragraph IV risk exists for GEODON?

Paragraph IV litigation is no longer the central risk. The principal Paragraph IV opportunity for ziprasidone occurred before generic entry. Current business exposure is instead linked to:

• Generic price erosion
• FDA manufacturing inspections
• Product shortages
• Supplier consolidation
• Hospital and pharmacy purchasing contracts
• Wholesaler inventory decisions
• State substitution rules
• Formulary placement

For an investor or licensee, a new Paragraph IV strategy against GEODON is unlikely to create material value because the original product is already genericized and the central patents have expired.

How large is the GEODON market?

The market is best analyzed in three segments:

Segment	2025 estimated annual value	Outlook
U.S. generic oral ziprasidone	$75 million-$125 million	Stable volume, continued price pressure
U.S. injectable ziprasidone	$20 million-$40 million	Supported by hospital and acute-care use
Non-U.S. markets	$50 million-$135 million	Fragmented, price-sensitive
Global total	$150 million-$300 million	Mature and largely flat

These are market-model estimates rather than reported Pfizer brand sales. Pfizer’s public reporting historically grouped or separately reported selected pharmaceutical products, but current financial disclosures do not provide a reliable standalone revenue line for GEODON.[5]

The injectable segment may have better pricing than oral capsules because hospitals value ready availability during acute agitation episodes. It remains smaller and more operationally sensitive than the oral market.

What are GEODON sales projections through 2030?

The following base case assumes stable treated-patient volume, no major new indication, no long-acting formulation launch, and continued generic competition.

Year	U.S. generic oral	U.S. injectable	International	Global estimated market
2025	$100 million	$30 million	$85 million	$215 million
2026	$98 million	$30 million	$86 million	$214 million
2027	$96 million	$31 million	$87 million	$214 million
2028	$95 million	$31 million	$88 million	$214 million
2029	$94 million	$32 million	$89 million	$215 million
2030	$93 million	$32 million	$90 million	$215 million

Scenario analysis

Scenario	2030 global market	Principal assumptions
Downside	$140 million-$170 million	Further generic price erosion, lower use in schizophrenia, stronger prescribing shift to newer agents
Base case	$200 million-$230 million	Stable volume, modest injectable growth, flat international demand
Upside	$275 million-$375 million	Supply disruptions raise prices, renewed clinical use, expanded hospital utilization, or differentiated formulation

The base case implies little or no real growth. Revenue may remain stable in nominal terms if injectable demand and international volume offset oral price erosion.

How does GEODON compare with competing antipsychotics?

Ziprasidone competes in a crowded atypical antipsychotic market.

Drug	Commercial position	Key advantage over ziprasidone	Key limitation
Aripiprazole	Large generic and long-acting market	Lower metabolic burden and injectable maintenance options	Akathisia and impulse-control concerns
Quetiapine	High-volume generic	Broad use across mood and sleep-related prescribing	Sedation, weight gain, metabolic effects
Risperidone	High-volume generic and long-acting products	Established depot options	Prolactin and extrapyramidal effects
Olanzapine	High-volume generic	Strong efficacy and broad clinical familiarity	Weight gain and metabolic risk
Lurasidone	Branded/generic transition depending market	Bipolar depression positioning	Food requirement and higher cost
Cariprazine	Newer branded product	Bipolar depression and schizophrenia positioning	Price and limited generic competition
Ziprasidone	Mature generic	Lower weight and metabolic liability relative to some agents	QT risk, food requirement, limited long-acting options

Ziprasidone’s clinical profile supports continued use where prescribers prioritize lower weight gain and lower metabolic impact. The food requirement, QT warning, and lack of a widely used long-acting injectable formulation constrain share expansion.[1]

What is the competitive landscape for generic ziprasidone?

Competition is fragmented and primarily price-based. Generic manufacturers compete through:

• Wholesale acquisition price
• Rebate and contract terms
• Supply continuity
• National distribution
• Hospital group purchasing organization contracts
• Availability across all four oral strengths
• Injectable product capacity
• Regulatory compliance

The largest commercial risk is supplier rationalization. A manufacturer with low volume may discontinue selected strengths, leaving the market to a smaller number of producers. That can temporarily improve pricing for remaining suppliers but creates supply and regulatory risk.

The oral capsule market has limited differentiation. An approved generic that is therapeutically equivalent to the reference product can typically be substituted under applicable state law and pharmacy rules. Competitive advantage therefore comes from cost, reliability, and distribution rather than patent exclusivity.

What patent litigation and settlement agreements affect GEODON?

Historical generic-entry litigation and settlement activity affected the timing of ziprasidone generic launch. Those matters have limited current commercial importance because generic entry occurred more than a decade ago.

No current settlement should be valued as a continuing market-exclusion asset unless it contains a surviving commercial restriction, license, or manufacturing covenant. For present-day diligence, the relevant questions are:

• Whether a supplier has an FDA-approved ANDA.
• Whether the supplier is actively shipping product.
• Whether the supplier has unresolved FDA compliance issues.
• Whether a process patent creates supplier-specific exposure.
• Whether a product liability or antitrust case affects contracting.
• Whether shortages or recalls have changed market share.

What licensing deals affect GEODON?

Pfizer developed and commercialized GEODON. The product’s licensing value has fallen sharply because the core molecule is off patent and generic suppliers have established market access.

Potential transaction value may still exist in:

• Regional distribution rights
• Hospital injectable supply contracts
• Manufacturing technology
• API supply
• Authorized-generic arrangements
• Product portfolios combining multiple generic psychiatric medicines

A licensing deal for the original branded product would generally have limited economic rationale unless it includes a differentiated formulation, supply advantage, or a high-value geographic market.

What generic launch scenarios exist for GEODON?

A new generic entrant would face a low-barrier regulatory pathway but a difficult commercial market.

Likely launch outcomes

1. A low-cost oral capsule entrant captures limited share through wholesalers and discount channels.
2. A supplier with reliable 20 mg, 40 mg, 60 mg, and 80 mg supply wins pharmacy contracts.
3. An injectable entrant gains value through hospital purchasing agreements.
4. A manufacturer exits after price erosion if it lacks scale.
5. A differentiated formulation obtains greater value only if it has clinical, regulatory, or reimbursement advantages.

A generic company should not assume that FDA approval produces rapid market penetration. Ziprasidone has an established supplier base, limited brand pull, and low unit pricing.

What geographic markets offer the greatest opportunity?

The U.S. offers the largest transparent regulatory market but also the strongest generic price pressure. Europe and other developed markets provide established demand but generally lower prices and country-specific reimbursement barriers. Emerging markets may offer volume growth but have more fragmented registration, tender, and distribution conditions.

Region	Opportunity	Main barrier
United States	Injectable contracts and broad pharmacy access	Low generic pricing
Western Europe	Stable schizophrenia and bipolar demand	National price controls
Latin America	Volume growth in selected markets	Registration and tender fragmentation
Asia-Pacific	Large patient population	Local manufacturers and low prices
Middle East and Africa	Institutional demand	Distribution and procurement risk

Manufacturing and API sourcing remain more important than patent rights. A supplier dependent on a single API site or one finished-dose facility faces greater commercial exposure than a supplier with redundant capacity.

What is the revenue exposure for Pfizer?

GEODON is no longer expected to be a material contributor to Pfizer’s consolidated revenue. Generic substitution and the expiration of exclusivity have removed the original branded pricing power. Pfizer’s current pharmaceutical portfolio is concentrated in larger growth products and newer therapeutic franchises, while mature products such as GEODON have limited strategic weight.[5]

Any remaining brand revenue is likely to be small relative to Pfizer’s total sales and should not materially affect valuation, earnings forecasts, or business-development strategy.

Key Takeaways

• GEODON is an off-patent ziprasidone product with established generic competition.
• U.S. exclusivity ended after expiration of the historical patent estate and generic entry in 2013.
• No biosimilar risk applies because ziprasidone is a small-molecule drug.
• Current market value is concentrated in generic oral capsules and hospital injectable supply.
• Estimated 2025 global market value is approximately $150 million to $300 million.
• Base-case global revenue is projected at roughly $215 million annually through 2030.
• Oral pricing should remain under pressure, while injectable supply may provide modest growth.
• The principal risks are generic price erosion, supplier exits, manufacturing compliance, and competition from newer antipsychotics.
• Patent litigation and Paragraph IV challenges are historical issues rather than current market barriers.
• A new entrant would need supply reliability, low manufacturing cost, or a differentiated formulation to achieve meaningful share.

FAQs

Is GEODON still sold under the brand name?

GEODON remains an FDA-approved brand, but most U.S. prescriptions are expected to be filled with generic ziprasidone because the product has lost exclusivity.

Is ziprasidone a high-revenue generic drug?

No. Ziprasidone is a mature, mid-volume generic with significantly lower revenue than high-use antipsychotics such as aripiprazole, quetiapine, risperidone, or olanzapine.

Does GEODON have a long-acting injectable version?

The FDA-approved injectable product is an intramuscular formulation for acute agitation associated with schizophrenia. It is not the same as a long-acting maintenance injectable administered over weeks or months.

Can a generic manufacturer launch a new GEODON product without a patent license?

A manufacturer can generally pursue an ANDA for an approved generic product after applicable patents and exclusivity have expired. It must still meet FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and regulatory compliance.

What could increase the value of the ziprasidone market?

A clinically differentiated formulation, improved food independence, a long-acting delivery system, supply shortages that raise pricing, or expanded use in hospital acute-care settings could increase market value. None should be assumed without FDA approval and commercial evidence.

References

1. U.S. Food and Drug Administration. (2023). Geodon (ziprasidone) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2001). FDA approves Geodon for treatment of schizophrenia. https://www.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
5. Pfizer Inc. (2013). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://www.pfizer.com/investors/financial-reports-annual-reports-and-proxy-information